 Purpura, Thrombocytopenic, Idiopathic
"Purpura, Thrombocytopenic, Idiopathic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
| Descriptor ID |
D016553
|
| MeSH Number(s) |
C15.378.100.802.687.600 C15.378.140.855.925.750.600 C15.378.463.740 C20.111.759 C20.841.600 C23.550.414.950.687.600 C23.888.885.687.687.600
|
| Concept/Terms |
Purpura, Thrombocytopenic, Idiopathic- Purpura, Thrombocytopenic, Idiopathic
- Idiopathic Thrombocytopenic Purpura
- Idiopathic Thrombocytopenic Purpuras
- Purpura, Idiopathic Thrombocytopenic
- Purpuras, Idiopathic Thrombocytopenic
- Thrombocytopenic Purpura, Idiopathic
- Thrombocytopenic Purpuras, Idiopathic
- Immune Thrombocytopenic Purpura
- Immune Thrombocytopenic Purpuras
- Purpura, Immune Thrombocytopenic
- Purpuras, Immune Thrombocytopenic
- Thrombocytopenic Purpura, Immune
- Thrombocytopenic Purpuras, Immune
- Immune Thrombocytopenia
- Immune Thrombocytopenias
- Thrombocytopenia, Immune
- Thrombocytopenias, Immune
- Thrombocytopenic Purpura, Autoimmune
- Werlhof Disease
- Disease, Werlhof
- Werlhof's Disease
- Disease, Werlhof's
- Werlhofs Disease
- Autoimmune Thrombocytopenia
- Autoimmune Thrombocytopenias
- Thrombocytopenia, Autoimmune
- Thrombocytopenias, Autoimmune
- Autoimmune Thrombocytopenic Purpura
- Autoimmune Thrombocytopenic Purpuras
- Purpura, Autoimmune Thrombocytopenic
- Purpuras, Autoimmune Thrombocytopenic
- Purpura, Thrombocytopenic, Autoimmune
|
Below are MeSH descriptors whose meaning is more general than "Purpura, Thrombocytopenic, Idiopathic".
- Diseases [C]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Blood Coagulation Disorders [C15.378.100]
- Purpura [C15.378.100.802]
- Purpura, Thrombocytopenic [C15.378.100.802.687]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.100.802.687.600]
- Blood Platelet Disorders [C15.378.140]
- Thrombocytopenia [C15.378.140.855]
- Thrombotic Microangiopathies [C15.378.140.855.925]
- Purpura, Thrombocytopenic [C15.378.140.855.925.750]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.140.855.925.750.600]
- Hemorrhagic Disorders [C15.378.463]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.463.740]
- Immune System Diseases [C20]
- Autoimmune Diseases [C20.111]
- Purpura, Thrombocytopenic, Idiopathic [C20.111.759]
- Purpura, Thrombocytopenic [C20.841]
- Purpura, Thrombocytopenic, Idiopathic [C20.841.600]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Hemorrhage [C23.550.414]
- Purpura [C23.550.414.950]
- Purpura, Thrombocytopenic [C23.550.414.950.687]
- Purpura, Thrombocytopenic, Idiopathic [C23.550.414.950.687.600]
- Signs and Symptoms [C23.888]
- Skin Manifestations [C23.888.885]
- Purpura [C23.888.885.687]
- Purpura, Thrombocytopenic [C23.888.885.687.687]
- Purpura, Thrombocytopenic, Idiopathic [C23.888.885.687.687.600]
Below are MeSH descriptors whose meaning is more specific than "Purpura, Thrombocytopenic, Idiopathic".
This graph shows the total number of publications written about "Purpura, Thrombocytopenic, Idiopathic" by people in this website by year, and whether "Purpura, Thrombocytopenic, Idiopathic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1994 | 2 | 1 | 3 | | 1996 | 0 | 1 | 1 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 5 | 0 | 5 | | 2012 | 4 | 0 | 4 | | 2013 | 5 | 0 | 5 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 5 | 0 | 5 | | 2017 | 2 | 0 | 2 | | 2018 | 6 | 0 | 6 | | 2019 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Purpura, Thrombocytopenic, Idiopathic" by people in Profiles.
-
Çekdemir D, Güvenç S, Özdemirkiran F, Eser A, Toptas T, Özkocaman V, Haydaroglu Sahin H, Ermis Turak E, Esen R, Cömert M, Sadri S, Aslaner M, Uncu Ulu B, Karakus A, Selim Bapur D, Alacacioglu I, Aydin D, Tekinalp A, Namdaroglu S, Ceran F, Tarkun P, Kiper D, Çetiner M, Yenerel M, Demir AM, Yilmaz G, Terzi H, Atilla E, Malkan ÜY, Acar K, Öztürk E, Tombak A, Sunu C, Salim O, Alayvaz N, Sayan Ö, Ozan Ü, Ayer M, Gökgöz Z, Andiç N, Kizilkiliç E, Noyan F, Özen M, Pepedil Tanrikulu F, Alanoglu G, Özkan HA, Aslan V, Çetin G, Akyol Erikçi A, Deveci B, Ersoy Dursun F, Dermenci H, Aytan P, Gündüz M, Karakus V, Özlü C, Demircioglu S, Akay Yanar OM, Özatli D, Ündar L, Tiftik EN, Türköz Sucak AG, Haznedaroglu I, Özcan M, Sencan M, Tombuloglu M, Özet G, Bilgir O, Turgut B, Özcan MA, Payzin KB, Sönmez M, Ayyildiz O, Dal MS, Ertop S, Turgut M, Soysal T, Kaya E, Ünal A, Pehlivan M, Atagündüz I, Tuglular Firatli T, Saydam G, Diz Küçükkaya R. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience Turk J Haematol. 2019 11 18; 36(4):230-237.
-
Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019 05 14; 3(9):1512-1518.
-
Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750.
-
Kim TO, Despotovic JM. Primary and Secondary Immune Cytopenias: Evaluation and Treatment Approach in Children. Hematol Oncol Clin North Am. 2019 06; 33(3):489-506.
-
Kim TO, Grimes AB, Kirk S, Arulselvan A, Lambert MP, Grace RF, Despotovic JM. Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. Am J Hematol. 2019 04; 94(4):461-466.
-
Neunert CE, Despotovic JM. Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. Pediatr Blood Cancer. 2019 04; 66(4):e27569.
-
Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):405-411.
-
O'Brien SH, Despotovic JM, Neunert CE. Intravenous Immunoglobulin Versus Anti-D Immunoglobulin: When Better Treatment May Not Be the Best Treatment. J Pediatr. 2019 01; 204:11-13.
-
Despotovic JM, Bussel JB. IVIg and Fc?RIIb in kids with ITP: individualizing therapy. Blood. 2018 08 30; 132(9):877-878.
-
Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018 07; 93(7):882-888.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|